Jeigu Jums kiltų klausimų arba reikėtų spausdintos mokomosios medžiagos, kreipkitės į Amryt Pharmaceuticals.

Registruotojas

Amryt Pharmaceuticals DAC
45 Mespil Road
Dublin 4
Airija

Medicininė informacija: tel.: +370 5 2369 140, el. paštas: medinfo.lithuania@swixxbiopharma.com.

Literatūra

1. Brown RJ, Araujo-Vilar D, Cheung PT, et al. The diagnosis and management of lipodistrofija syndromes: a multi-society practice guideline. J Clin Endocrinol Metab 2016;101 :4500-11.

2. Rodriguez AJ, Mastronardi CA, Paz-Filho GJ. New advances in the treatment of generalized lipodistrofija: role of metreleptin. Ther Clin Risk Manag201 S;11 :1391-400.

3. Gupta N, Asi N, Farah W, et al. Clinical features and management of non-HIV related lipodistrofija in children: a systematic review. J Clin Endocrinol Metab 2017;102:363-74.

4. Mantzoros CS, Magkos F, Brinkoetter M, et al. Leptin in human physiology and pathophysiology. Am) Physiol Endocrinol Metab 2011 ;301 :E567-84.

5. Chan JL Oral EA. Clinical classification and treatment of congenital and acquired lipodistrofija. Endocr Pract 2010;16:310-23.

6. Amryt Pharmaceuticals DAC. Myalepta Preparato charakteristikų santrauka.